Loading...
Market
Which company will first announce the development of an IL-7 based treatment for Celiac Disease?
2
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
GlaxoSmithKline • 25%
Other • 25%
Press releases from pharmaceutical companies, official announcements
Story
NIAID-Funded Researchers, StanfordMed Identify IL-7 as Potential Treatment Target for Celiac Disease in Nature
Jul 25, 2024, 11:10 AM
Researchers funded by the National Institute of Allergy and Infectious Diseases (NIAID) have developed an organoid model of Celiac Disease that replicates the tissue structure and immune features of the human intestine. This model, credited to StanfordMed, has identified Interleukin-7 (IL-7) as a potential treatment target. IL-7 is a gluten-inducible pathogenic modulator that regulates CD8+ T-cell NKG2C/D expression and is necessary for epithelial destruction in the gut. The findings, published in Nature, highlight a new link between gluten and intestinal damage, providing a promising direction for future Celiac Disease therapies.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Novartis • 25%
Calliditas • 25%
Ligand Partner • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Nature • 25%
The Lancet • 25%
JAMA • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%